Qrons Inc

NEW
OTCPK:QRON (USA)  
$ 0.011 (0%) 10:08 PM EST
At Loss
Market Cap:
$ 199.00K
Enterprise V:
$ 494.00K
Volume:
0
Avg Vol (2M):
19.48K
Trade In:
Volume:
0
At Loss
Avg Vol (2M):
19.48K

Business Description

Description
Qrons Inc. is a biotechnology company, dedicated to developing biotech products, treatments, and technologies to combat neuronal and infectious diseases with a focus on antibiotic-resistant bacteria, which is becoming the prominent and rapidly growing world-wide cause of illness and death. The technology would treat a wide range of neurodegenerative diseases. The treatment integrates proprietary, engineered mesenchymal stem cells, 3D printable scaffolding, smart materials, and a novel delivery system. The company has two product candidates, QS100TM for treating penetrating brain injuries and QS200TM for treating concussions and other diffused axonal injuries.

Financial Strength

Name Current Vs Industry Vs History

Growth Rank

Name Current Vs Industry Vs History

Momentum Rank

Name Current Vs Industry Vs History
5-Day RSI
38.96
9-Day RSI
44.1
14-Day RSI
46.28
3-1 Month Momentum %
0.9
6-1 Month Momentum %
0.9
12-1 Month Momentum %
-77.6

Liquidity Ratio

Name Current Vs Industry Vs History

Dividend & Buy Back

Name Current Vs Industry Vs History

Profitability Rank

Name Current Vs Industry Vs History

GF Value Rank

Name Current Vs Industry Vs History

Financials

QRON's 30-Y Financials
Income Statement Breakdown FY
Not Enough Data
Balance Sheet Breakdown
Not Enough Data
Cashflow Statement Breakdown
Not Enough Data

Operating Revenue by Business Segment

Operating Revenue by Geographic Region

Historical Operating Revenue by Business Segment

Historical Operating Revenue by Geographic Region

5-Step DuPont Analysis as of
Not Enough Data

Guru Trades

See Details
To

Insider Trades

See Details
To

Gurus Latest Trades with OTCPK:QRON

No Available Data

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
Log
Bar
To

Annualized Return %  

Symbol
1 Week
1 Month
3 Months
6 Months
YTD
1 Year
3 Years
5 Years
10 Years

Total Annual Return %  

Symbol
2026
2025
2024
2023
2022
2021
2020
2019
2018
2017

Qrons Inc Executives

Details

GF Valueâ„¢

Valuation Chart

Year:

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil $)
EPS (TTM) ($) 0.002
Beta -0.7519
3-Year Sharpe Ratio -0.76
3-Year Sortino Ratio -0.91
Volatility % 110.4
14-Day RSI 46.28
14-Day ATR ($) 0.000234
20-Day SMA ($) 0.0111
12-1 Month Momentum % -77.6
52-Week Range ($) 0.0111 - 0.07
Shares Outstanding (Mil) 17.91

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 0
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Qrons Inc Filings

Filing Date Document Date Form
No Filing Data

Qrons Inc Stock Events

Financials Calendars
Event Date Price ($)
No Event Data

Qrons Inc Frequently Asked Questions

What is Qrons Inc(QRON)'s stock price today?
The current price of QRON is $0.01. The 52 week high of QRON is $0.07 and 52 week low is $0.01.
When is next earnings date of Qrons Inc(QRON)?
The next earnings date of Qrons Inc(QRON) is .
Does Qrons Inc(QRON) pay dividends? If so, how much?
Qrons Inc(QRON) does not pay dividend.

Guru Commentaries on OTCPK:QRON

No articles.

Press Release

Subject Date
Qrons / First Person Provides Shareholder Update and Strategic Overview 2025-07-10
First Person and Qrons Complete Merger, Creating a Publicly Traded Leader in Cognitive Wellness & Functional Beverages 2025-02-04
Qrons Announces the Addition of Professor Shiri Navon-Venezia to its Scientific Advisory Board to Beef up its Team, as Part of its New Sepsis Research Program 2023-11-20
Qrons Announces Launch of its New Website in Furtherance of its Neuronal and Infectious Disease Treatments Development, Including Sepsis 2023-08-23
Qrons Announces the Filing of a Provisional Patent Application in Furtherance of its Neuronal and Infectious Disease Treatments Development, Including Sepsis 2023-08-14
Qrons Announces the Signing of a License Agreement Term Sheet as Part of New Research Program to Experiment and Commercialize the Therapeutic Effect of Certain Tellurium Based Compounds on Antibiotic Resistance Bacterial Infections, Sepsis and Traumatic B 2023-07-20
Qrons files U.S. National Phase of its Patent Application in Furtherance of its QS200 Product Candidate for Therapeutic Polypseudorotaxane Hydrogels 2023-03-22
Qrons Announces Engagement of Israeli Intellectual Property Law Firm IPK to Develop Roadmap for Its New Product Line 2023-01-17
Qrons Announces a New Pre-Clinical Research Program to Test the Efficacy of Tellurium Based Compounds, in Combination with its QS200(TM) Product Candidate or Independently, in Treating Diffused Axonal Injuries and Antibiotic Resistant Bacteria and Sepsis 2022-12-14
Qrons Announces Filing Of Provisional Patent Application In Furtherance Of Its QS200 Product Candidate 2022-04-12
10/Page

Articles on Qrons Inc

No articles.

Headlines

See More
  • 1
No news.
  • 1